作者: H-P Lin , Y-P Wang , J-S Chia , C-P Chiang , A Sun
DOI: 10.1111/J.1601-0825.2010.01711.X
关键词:
摘要: Oral Diseases (2010) 17, 95–101 Objectives: The objective of this study was to test the efficacy three different treatment modalities on reduction serum anti-gastric parietal cell autoantibody (GPCA) level in GPCA-positive oral lichen planus (OLP) patients. Materials and methods: Of 147 OLP patients, 100 were treated with levamisole plus vitamin B12, 10 B12 only 37 only. GPCA levels patients measured at baseline after treatment. Results: Treatment for a period 2–50 months 4–44 months could effectively reduce high undetectable respectively. However, not modulate mean titer significantly lower patients. A 92% recurrence rate found 25 receiving no further during GPCA-negative remission period. Conclusion: For modality containing can level. underlying autoimmune atrophic gastritis trait should receive maintenance life.